Details for Patent: 10,407,393
✉ Email this page to a colleague
Which drugs does patent 10,407,393 protect, and when does it expire?
Patent 10,407,393 protects LENVIMA and is included in one NDA.
This patent has thirty-nine patent family members in twenty-four countries.
Summary for Patent: 10,407,393
| Title: | High-purity quinoline derivative and method for manufacturing same |
| Abstract: | Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less. ##STR00001## |
| Inventor(s): | Nakamura; Taiju (Kamisu, JP), Abe; Taichi (Kamisu, JP), Miyashita; Yusuke (Kamisu, JP), Kuroda; Hirofumi (Kamisu, JP), Ayata; Yusuke (Kamisu, JP), Akao; Atsushi (Kamisu, JP) |
| Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
| Application Number: | 16/229,805 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,407,393 |
|
Patent Claim Types: see list of patent claims | Compound; |
Recent additions to Drugs Protected by US Patent 10,407,393
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE | 206947 | Feb 13, 2015 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,407,393
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,407,393
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2014-174062 | Aug 28, 2014 |
| Japan | 2015-034729 | Feb 25, 2015 |
International Family Members for US Patent 10,407,393
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 101695 | ⤷ Try a Trial | |||
| Australia | 2015309862 | ⤷ Try a Trial | |||
| Brazil | 112017002827 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
